AstraZeneca PLC (AZNCF)
| Market Cap | 289.37B +37.1% |
| Revenue (ttm) | 58.13B +13.5% |
| Net Income | 9.40B +44.7% |
| EPS | 6.02 +45.0% |
| Shares Out | n/a |
| PE Ratio | 30.79 |
| Forward PE | 18.58 |
| Dividend | 3.13 (1.71%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 1,738 |
| Average Volume | 1,993 |
| Open | 183.00 |
| Previous Close | 183.17 |
| Day's Range | 182.28 - 187.10 |
| 52-Week Range | 122.26 - 195.00 |
| Beta | 0.19 |
| RSI | 53.34 |
| Earnings Date | Feb 10, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial StatementsNews
AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC
The agreement to gain rights outside of China to a portfolio of experimental obesity and diabetes drugs could be valued at billions of dollars.
World leaders descend on Beijing as 2026 kicks off, hedging against U.S. disruptions
At least five world leaders have visited Beijing in January alone. The high-level visits come as countries navigate tense U.S. relations.
China's CSPC Pharmaceutical inks deal with AstraZeneca for weight loss therapy
CSPC Pharmaceutical Group said on Friday it had entered an agreement with UK drugmaker AstraZeneca for the development of innovative long-acting peptide medicines for obesity and weight-related condit...
AstraZeneca sets out $15 billion China investment during Starmer visit
UK drugmaker AstraZeneca said on Thursday it would invest $15 billion in China through 2030 to expand medicines manufacturing and research and development, an announcement made during British Prime Mi...
University of Virginia Signs Master Research Collaboration Agreement with AstraZeneca to Accelerate Pre-Clinical Innovation
Agreement builds on long-established partnership and demonstrates the strength and importance of industry/academic scientific collaborations Agreement builds on long-established partnership and demons...
Airbus, AstraZeneca and HSBC executives join UK's Starmer on high-stakes China trip
Starmer brings nearly 60 business and cultural groups on first U.K. leader visit to China in eight years. Talks with Xi and Li focus on trade, investment and national security.
Astrazeneca CEO Soriot to join Starmer delegation to China, source says
UK-headquartered pharmaceutical firm AstraZeneca's AZN.L) CEO Pascal Soriot will join Prime Minister Keir Starmer's trip to China this week, said a source familiar with the matter, as Britain seeks to...
FMB WEALTH MANAGEMENT Buys 2,477 Shares of AstraZeneca PLC (AZN)
FMB WEALTH MANAGEMENT Buys 2,477 Shares of AstraZeneca PLC (AZN)
Ledyard National Bank Buys 2,245 Shares of AstraZeneca PLC (AZN)
Ledyard National Bank Buys 2,245 Shares of AstraZeneca PLC (AZN)
Independence Bank of Kentucky Buys 77 Shares of AstraZeneca PLC (AZN)
Independence Bank of Kentucky Buys 77 Shares of AstraZeneca PLC (AZN)
After Canada, Another US Ally Set To Revive Old Trade Ties With China: Report
The UK and China are reportedly set to reinvigorate their ‘golden era’ business dialogue during Prime Minister Keir Starmer ‘s visit to Beijing next week. UK, China Move to Reset Business Ties The two...
TOTH FINANCIAL ADVISORY CORP Buys 18 Shares of AstraZeneca PLC (AZN)
TOTH FINANCIAL ADVISORY CORP Buys 18 Shares of AstraZeneca PLC (AZN)
AstraZeneca To Delist ADRs From Nasdaq By January, Eyes Broader Investor Reach
AstraZeneca plans to delist from Nasdaq and move ... Full story available on Benzinga.com
AstraZeneca To Delist ADRs From Nasdaq By January, Eyes Broader Investor Reach
AstraZeneca Plc (NASDAQ: AZN) said Tuesday it will voluntarily delist its American Depositary Shares and certain guaranteed debt securities from the Nasdaq as it transitions to a direct stock listing ...
AstraZeneca PLC (AZN) Stock Price Down 4.11% on Jan 20
AstraZeneca PLC (AZN) Stock Price Down 4.11% on Jan 20
Wealth Management Associates, Inc. Buys 3,275 Shares of AstraZeneca PLC (AZN)
Wealth Management Associates, Inc. Buys 3,275 Shares of AstraZeneca PLC (AZN)
AstraZeneca (AZN) Shifts Listing from Nasdaq to NYSE
AstraZeneca (AZN) Shifts Listing from Nasdaq to NYSE
Oakmark International Fund: adds AZN, SNY, and UL; exits NVS KMTUY
AstraZeneca (AZN) to Transition to NYSE, Delisting from Nasdaq
AstraZeneca (AZN) to Transition to NYSE, Delisting from Nasdaq
AstraZeneca (AZN) to Consolidate Stock Listings on NYSE
AstraZeneca (AZN) to Consolidate Stock Listings on NYSE
AstraZeneca to commence trading on NYSE in February
AstraZeneca Expects Ordinary Shares, Debt Securities To Commence Trading On NYSE From Feb. 2
(RTTNews) - AstraZeneca PLC (AZN, AZN.L, ZEG.DE, AZN.ST) issued notice of the voluntary withdrawal from listing on The Nasdaq Stock Market of its American Depositary Shares, or the ADSs and debt secur...
AstraZeneca to delist from Nasdaq, join NYSE in February
AstraZeneca on Tuesday said it would delist its American Depositary Shares and debt securities from Nasdaq and complete a direct listing of its ordinary shares and debt on the New York Stock Exchange,...
LARGE CAP INTERNATIONAL PORTFOLIO Sells 45,475 Shares of AstraZeneca PLC (AZN)
LARGE CAP INTERNATIONAL PORTFOLIO Sells 45,475 Shares of AstraZeneca PLC (AZN)
AstraZeneca (AZN): EMA Considers Enhertu for Breast Cancer Treatment
AstraZeneca (AZN): EMA Considers Enhertu for Breast Cancer Treatment